Antagonists of TNF action: clinical experience and new developments

Author： Kontermann Roland E   Scheurich Peter   Pfizenmaier Klaus  

Publisher： Informa Healthcare

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.4, Iss.3, 2009-03, pp. : 279-292

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A clinical conundrum: the detrimental effect of TNF antagonists in multiple sclerosis

By Dendrou Calliope A   Bell John I   Fugger Lars  

Pharmacogenomics, Vol. 14, Iss. 12, 2013-09 ,pp. : 1397-1404

Future Medicine

Access to resources Recommend Favorite

Safety of TNF antagonists

By  

Reactions Weekly, Vol. 1, Iss. 1210, 2008-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Safety of TNF antagonists

By  

Inpharma, Vol. 1, Iss. 1646, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Predictors of Response to TNF Antagonists

By  

Current Pharmaceutical Design, Vol. 21, Iss. 2, 2015-01 ,pp. : 221-232

Bentham Science Publishers

Access to resources Recommend Favorite

New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists

By Schultze-Mosgau Askan   Griesinger Georg   Altgassen Christopher   von Otte Soeren   Hornung Daniela   Diedrich Klaus  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 9, 2005-09 ,pp. : 1085-1097

Informa Healthcare

Access to resources Recommend Favorite